Drug combination delivered by nanoparticles may help in melanoma treatment

HERSHEY, Pa. — The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers.

New driver, target in advanced mucosal melanoma

Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted treatments and immunotherapies have dramatically improved the prognosis for many patients with sun-associated melanomas, these treatments are ineffective in the mucosal form of […]

Melanoma Takes Advantage of Missing Tumor-Suppressors to Resist Immunotherapy

Missing tumor-suppressing genes are the culprit behind resistance to immune checkpoint blockade drugs, investigators recently found.

Array BioPharma And Columbus’s Egg

In my first articles as a Seeking Alpha contributor, I’ve highlighted the potential of three widely differing companies: Bristol-Myers Squibb (NYSE:BMY), Tracon (NASDAQ:TCON) and Innate Pharma (OTCPK:IPHYF).

Cancer in the News

Feature Articles

Not Enough Melanoma Survivors Limit Exposure to Sun or Protect Skin

While most melanoma survivors are more likely to limit their exposure to the sun and protect their skin than people who never had the disease, a considerable number still report getting sunburns and some continue to used a tanning booth, according to a new study.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Cottesloe Melanoma March to raise awareness of skin cancer

ROOF carpenter and melanoma sufferer Brad Gray (34) says everyone has the tools to protect against the sun.

Read the full story

Posted in Melanoma In The News, Patient Events

Binimetinib Delayed Progression of NRAS-Mutant Melanoma

The MEK inhibitor binimetinib improved progression-free survival compared with dacarbazine in patients with NRAS-mutant melanoma, according to the phase III results of the NEMO trial published in Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Array BioPharma Provides NEMO Update

BOULDER, Colo., March 19, 2017 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has withdrawn from the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products 2 its new drug application (NDA) for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutationally-driven subset of skin cancer.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories